UCB SA (LTS:0NZT)

€ 126.35 2.1 (1.69%) Market Cap: 24.04 Bil Enterprise Value: 26.03 Bil PE Ratio: 72.05 PB Ratio: 2.68 GF Score: 70/100

Full Year 2023 Ucb SA Earnings Call Transcript
Feb 28, 2024

€104.9 (+8.22%)

Earnings
Half Year 2023 Ucb SA Earnings Call Transcript
Jul 27, 2023

€80.98 (+0.25%)

Earnings
Ucb SA Update on BKZ US Review and Rystiggo US Approval Call Transcript
Jun 27, 2023
Full Year 2022 Ucb SA Earnings Call Transcript
Feb 22, 2023

€80.84 (+2.15%)

Earnings
Full Year 2021 UCB SA Earnings Call Transcript
Feb 24, 2022

€92.12 (+3.98%)

Earnings
UCB SA to Acquire Zogenix Inc Capital Markets Call Transcript
Jan 19, 2022
Half Year 2021 UCB SA Earnings Call Transcript
Jul 29, 2021

€91.33 (+1.44%)

Earnings
Full Year 2020 UCB SA Earnings Call Transcript
Feb 25, 2021

€86.51 (+6.40%)

Earnings
UCB SA at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Ucb SA Analysts and Investors Conference Call Transcript
Nov 12, 2020
Q2 2020 Ucb SA Earnings Call Transcript
Jul 27, 2020

€111.2 (+0.66%)

Earnings
Full Year 2019 Ucb SA Earnings Call Transcript
Feb 20, 2020

€92.68 (+3.30%)

Earnings
Ucb SA to Acquire Ra Pharmaceuticals Inc Call Transcript
Oct 10, 2019
Q2 2019 Ucb SA Earnings Call Transcript
Jul 25, 2019

€71.46 (-5.19%)

Earnings
Q4 2018 Ucb SA Earnings Call Transcript
Feb 28, 2019

€74.25 (-3.48%)

Earnings

Ucb SA Analysts and Investors Conference Call Transcript

Nov 12, 2020 / 03:00PM GMT

Release Date Price: €94.05 (-2.99%)

Transcript

Antje Witte

UCB SA - Head of IR

Good morning, good afternoon from my side. Welcome to our call introducing gene therapy. I'm happy to hand you over to Dhaval Patel, our Chief Scientific Officer, who will give you a brief presentation and who then, in the Q&A session, will be joined by his team, namely Martin Citron, Head of Neurology Therapeutic Area; and Roger Palframan, Head of External Innovation & U.S. Discovery Science.

This presentation and following Q&A session is covered by this disclaimer and safe harbor statement. We kindly ask you to read this carefully, perhaps not now, but it's also available on our website, and be informed about this.

I'm now happy to give over -- to hand over to our Chief Scientific Officer, Dhaval Patel. Thank you very much.

Dhavalkumar D. Patel

UCB SA - Executive VP & Chief Scientific Officer

Hey, everybody. Thanks for taking the time to join. It's my pleasure to speak to you today about UCB's entry into gene therapy.

As you all know, we have a strong legacy in the chemical

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.